METHYLGUAZONE, VINDESINE AND CISPLATIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MALIGNANT-LYMPHOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY (PA482)
Ph. Wiernik et al., METHYLGUAZONE, VINDESINE AND CISPLATIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MALIGNANT-LYMPHOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY (PA482), Leukemia & lymphoma, 30(5-6), 1998, pp. 619-624
A new regimen not cross-resistant with standard regimens was developed
for patients with relapsed or refractory Hodgkin's disease and non-Ho
dgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M-2 given
intravenously on day 1, Vindesine, 3 mg/M-2 given intravenously on day
s 1 and 8 (and also on day 15 of the first cycle only), and methylguaz
one, 600 mg/M-2 given intravenously on days 8 and 15,Courses were repe
ated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4
with Hodgkin's lymphoma) were treated and all were evaluable for respo
nse and toxicity. There were 5 complete and 14 partial responses for a
total response rate of 49% (C.I. = 35%-63%). The median durations of
partial and complete response were only 2.8 and 4.2 months, respective
ly. Only one patient remained in complete response for more than a yea
r. There was one treatment-related death from renal failure on the stu
dy. Although this regimen was, in general, well tolerated the results
are disappointing and seem no better than those obtained with many oth
er salvage regimens for lymphoma.